Melanoma

Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy. Read More ›

The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting. Read More ›